Forskning
Udskriv Udskriv
Switch language
Hvidovre Hospital - en del af Københavns Universitetshospital
Udgivet

No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  • Annette J Vangsted
  • Karen Søeby
  • Tobias W Klausen
  • Niels Abildgaard
  • Niels F Andersen
  • Peter Gimsing
  • Henrik Gregersen
  • Ulla Vogel
  • Thomas Werge
  • Henrik B Rasmussen
Vis graf over relationer
The response to treatment varies among patients with multiple myeloma and markers for prediction of treatment outcome are highly needed. Bioactivation of cyclophosphamide and thalidomide, and biodegradation of bortezomib, is dependent on cytochrome P450 metabolism. We explored the potential influence of different polymorphisms in the CYP enzymes on the outcome of treatment.
OriginalsprogEngelsk
TidsskriftB M C Cancer
Vol/bind10
Sider (fra-til)404
Antal sider8
ISSN1471-2407
DOI
StatusUdgivet - 4 aug. 2010

ID: 31070945